Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the ...
Three out of four patients treated so far with head and neck cancers experienced disease control, with one complete response and one partial response observed in the first subset of patients Initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results